The Lancet Oncology#health
[Personal View] Challenges in the use of the European Society for Radiotherapy and Oncology–European Organisation for Research and Treatment of Cancer oligometastatic disease classification system in ovarian cancertranslating…
Factuality: 72/100UnknownLancet Publishing
The oligometastatic disease classification system, developed within the European Society for Radiotherapy and Oncology (ESTRO)–European Organisation for Research and Treatment of Cancer (EORTC) OligoCare project, has been proposed for prognostic stratification and clinical trial…